- Research article
- Open Access
Implications of the structure of human uridine phosphorylase 1 on the development of novel inhibitors for improving the therapeutic window of fluoropyrimidine chemotherapy
© Roosild et al; licensee BioMed Central Ltd. 2009
- Received: 27 October 2008
- Accepted: 16 March 2009
- Published: 16 March 2009
Uridine phosphorylase (UPP) is a key enzyme of pyrimidine salvage pathways, catalyzing the reversible phosphorolysis of ribosides of uracil to nucleobases and ribose 1-phosphate. It is also a critical enzyme in the activation of pyrimidine-based chemotherapeutic compounds such a 5-fluorouracil (5-FU) and its prodrug capecitabine. Additionally, an elevated level of this enzyme in certain tumours is believed to contribute to the selectivity of such drugs. However, the clinical effectiveness of these fluoropyrimidine antimetabolites is hampered by their toxicity to normal tissue. In response to this limitation, specific inhibitors of UPP, such as 5-benzylacyclouridine (BAU), have been developed and investigated for their ability to modulate the cytotoxic side effects of 5-FU and its derivatives, so as to increase the therapeutic index of these agents.
In this report we present the high resolution structures of human uridine phosphorylase 1 (hUPP1) in ligand-free and BAU-inhibited conformations. The structures confirm the unexpected solution observation that the human enzyme is dimeric in contrast to the hexameric assembly present in microbial UPPs. They also reveal in detail the mechanism by which BAU engages the active site of the protein and subsequently disables the enzyme by locking the protein in a closed conformation. The observed inter-domain motion of the dimeric human enzyme is much greater than that seen in previous UPP structures and may result from the simpler oligomeric organization.
The structural details underlying hUPP1's active site and additional surfaces beyond these catalytic residues, which coordinate binding of BAU and other acyclouridine analogues, suggest avenues for future design of more potent inhibitors of this enzyme. Notably, the loop forming the back wall of the substrate binding pocket is conformationally different and substantially less flexible in hUPP1 than in previously studied microbial homologues. These distinctions can be utilized to discover novel inhibitory compounds specifically optimized for efficacy against the human enzyme as a step toward the development of more effective chemotherapeutic regimens that can selectively protect normal tissues with inherently lower UPP activity.
- Purine Nucleoside Phosphorylase
- Human Enzyme
- Uridine Phosphorylase
- Ribose Sugar
- Side Chain Oxygen Atom
Uridine phosphorylase (UPP; EC 126.96.36.199) is a ubiquitous enzyme involved in pyrimidine salvage and maintenance of uridine homeostasis [1–3]. It catalyzes the reversible phosphorolysis of uracil ribosides and analogous compounds to their respective nucleobases and ribose-1-phosphate. The structural mechanisms underlying the catalytic activity of this enzyme have been extensively studied through analysis of E. coli UPP (EcUPP) [4–7] and more recently the S. typhimurium homologue . These structures have shown UPP to belong to the nucleoside phosphorylase (NP) super-family of proteins in the NP-I subset of proteins possessing α/β folds and trimeric or hexameric (through trimerization of dimers) quaternary assemblies . Additionally, based on conservation of sequence and ligand binding site architecture, it is probable that the general catalytic mechanism is retained between UPP and related purine nucleoside phosphorylases (PNPs).
Humans possess two isoforms of UPP (hUPP1  & hUPP2 ) of which hUPP1 is more widely distributed, more abundantly expressed, and better characterized. hUPP1 has been a subject of interest to cancer researchers due to its role in the activation of pyrimidine nucleoside analogues used in chemotherapy, such as 5-fluorouracil (5-FU)  and its prodrug, capecitabine. Further, elevated levels of hUPP1 activity in certain tumours may contribute positively to the selectivity of these cancer-killing reagents . Other studies have explored the potential of hUPP1 inhibitors as a means of raising endogenous uridine levels during the course of fluoropyrimidine nucleoside treatment, in order to protect normal tissues from the toxicity of these drugs [14, 15]. These inhibitors have been developed from a family of acyclouridine analogues and include 5-benzylacyclouridine (BAU) , a compound that has been investigated in clinical trials for its ability to increase the therapeutic index of 5-FU through induction of such uridine-mediated rescue . While structures of EcUPP with BAU and related molecular analogues have revealed the general mechanistic features of this competitive inhibitor which obstructs the enzyme's active site , the structure of hUPP1 and the details of its specific interactions with this potentially clinically-valuable drug have not been elucidated.
Summary of crystallographic data and model refinement
a = 66.20 Å
a = 253.78 Å
b = 74.44 Å
b = 253.78 Å
c = 262.71 Å
c = 253.78 Å
Number of reflections
Number of monomers/A.U.
Rmsd bond lengths
Rmsd bond angles
Most favored regions
Additional allowed regions
hUPP1 is a dimeric enzyme
Overall structure of hUPP1
The alterations occurring around the region of microbial helix α3 also provide a molecular explanation for the loss of trimerization of dimers in the human enzyme. The long loop preceding β* in hUPP1 sterically interferes with the formation of the protein-protein interface for dimer oligomerization seen in previous structures. Additionally, the hydrophobic residues ('FPAV') that form the core of the trimer assembly surface in EcUPP have been mutated to more polar, solvent-compatible residues in hUPP1 (Figure 2C).
Binding of the inhibitor BAU to the hUPP1 active site
Additional differences between the active sites of human and bacterial enzymes become apparent when the analysis is extended to regions of these proteins contacting chemical modifications of acyclouridine analogues such as BAU. The benzyl ring of this molecule is π-stacked on one side by Tyr35, a residue that is conserved as phenylalanine in microbes. More significantly, the edge of this benzyl moiety interacts with a loop region that is structured very differently in hUPP1 than in EcUPP. In structures of the E. coli enzyme, the equivalent loop appears highly flexible, to the point of frequently being too disordered for modelling. These studies concluded that this loop undergoes an 'induced-fit' conformational change upon ligand or inhibitor binding (Figure 4B) . In contrast, the same loop in hUPP1 is rigid with relatively lower thermal factors and remains structurally unaltered by BAU binding. This stability is likely the result of the insertion within this loop in hUPP1 of two additional residues as compared to bacterial variants (Figure 2C). These structural differences have major implications toward understanding how various other existing or theoretical acyclouridine derivatives will interact with the human enzyme.
Ligand induced motion between hUPP1 domains
Human uridine phosphorylase 1 has been the molecular target for the design of specific inhibitors intended to boost endogenous uridine levels for the purpose of rescuing normal tissues from the toxicity of fluoropyrimidine nucleoside chemotherapeutic agents. The structures reported here reveal significant differences between hUPP1 and previously characterized microbial UPPs that have meaningful implications toward the rational design of novel reagents with improved potency. In contrast to expectations, hUPP1 is dimeric, having lost the higher order assembly (trimer-of-dimers) that results in hexameric rings in more primitive UPPs. Possibly as a direct consequence, hUPP1 has two major architectural modifications, both of which serve to increase the contact surface area between domains. These alterations likely increase the stability of dimer association, potentially as compensation for stability lost on dissolution of the larger ring complex.
Another implication of the loss of hexameric structure appears to be that the human enzyme possesses greater inter-domain flexibility than its microbial counterparts. While the ability of enzymes to 'breathe' to facilitate substrate and product exchange is a common phenomenon, it has not been observed in previous studies of UPPs. Whether this inter-subunit motion has a meaningful affect on the kinetics and catalytic turnover rates of hUPP1, in comparison to EcUPP, remains to be investigated. However, the 'open' conformation of hUPP1 provides the opportunity to potentially develop a novel class of allosteric inhibitors of this enzyme that lock the protein in a functionally disabled form, with its catalytic residues too separated to lyse substrates.
In this report, we present the first structures of human uridine phosphorylase 1. The specific biochemical features of the human version of this ubiquitous enzyme revealed by these studies offer improved understanding of how clinically-evaluated specific inhibitors, such as BAU, bind to and inactivate this protein. The molecular details regarding the residues of hUPP1 lining the binding pocket for such acyclouridine derivatives offer clear approaches to improving the specificity of these compounds to the human enzyme. Previous studies have successfully increased the affinity of acyclouridine analogues to hUPP1 through the creation of more hydrophobic variations of BAU such as 5-m-benzyloxybenzylacyclouridine . Given the recent revelation that BAU may have cross-reactivity to other human enzymes such as aldehyde oxidase , designing rational alterations in the moieties extending beyond the first benzyl ring may result in substantial improvements in both compound activity and selectivity. Extremely high affinity inhibitors of human PNP (7 pM) have been obtained by using transition state mimetics derived from immucillins . With the conservation of active site structure and catalytic mechanism among all NP-I family members, similarly potent antagonists of hUPP1 should be creatable. When combined with strategically selected structure-based modifications to optimize specificity for this enzyme, there is a strong potential to develop improved pharmaceuticals for incorporation into novel chemotherapeutic regimens with increased efficacy and reduced toxicity.
Protein production and purification
Production and isolation of hUPP1 was conducted as previously reported  and followed standard laboratory protocols for recombinant bacterial protein expression and purification. In brief, pQE plasmid containing an N-terminally six histidine-tagged construct of the enzyme was transformed into BL21(DE3) E. coli. Freshly transformed colonies were cultured in Terrific Broth and induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at an O.D. of 1.0. Growth was continued overnight at 18°C. Cells were harvested and resuspended in 50 mM Tris buffer pH 8.0, 300 mM KCl, 10% glycerol with 20 mM imidazole. The bacteria were then disrupted by sonication on ice and membranes with other insoluble material were pelleted by high speed centrifugation (100,000 × g). Recombinant hUPP1 was subsequently purified from the resulting supernatant using Ni-NTA affinity chromatography and batch eluted with 500 mM imidazole added to the sonication buffer above. Further purification was conducted using gel filtration chromatography over Superdex 200 resin equilibrated in 300 mM KCl, 50 mM Tris buffer pH 8.0 with 1 mM Tris (2-carboxy-ethyl) phosphine (TCEP). The final sample was verified to be homogenous by SDS-PAGE experiments and used directly for crystallization or biochemical analysis, as it was discovered that reduction of the salt concentration of the buffer below 250 mM at any point during the protein preparation process led to protein aggregation and precipitation.
Large scale preparations of hUPP1 recombinant protein provided the starting material for initial crystallization trials. Purified hUPP1 at 4 mgs/mL was subject to crystal screening utilizing the JCSG+ crystallization screen (Qiagen) with supplementation of potential ligands BAU, uridine and phosphate. Initial promising leads with BAU containing 25% PEG 3350 and Bis-Tris buffer pH 5.5 were optimized to produce large (> 100 microns/dimension) crystals. Crystals would grow in the same condition in two morphologies: rods and pyramids; however, the triganol crystals invariably possessed high mosaicity and low resolution diffraction characteristics. The largest and best diffracting rod crystals were grown in 17% PEG 3350, 100 mM Bis-Tris buffer pH 5.5, 300 mM KCl, 30 mM MgCl2 with 1 mM BAU added to the protein (3 mgs/mL). Crystals were frozen by submersion in liquid nitrogen after a few seconds incubation in cryoprotectant containing the above constituents supplemented with 23% ethylene glycol. The ligand-free crystal form of hUPP1 was found in conditions optimized to 1.2 M (NH4)2SO4, 100 mM Bis-Tris buffer pH 5.5, with 1–2% MPD and protein concentration at 2–3 mgs/mL. Crystals could be grown to very large diamond-shaped proportions, exceeding 300 microns on each edge. These crystals were frozen by submersion in liquid nitrogen after a few seconds incubation in cryoprotectant containing the above constituents supplemented with 25% glycerol.
Data collection/processing and structure determination
Data was collected at SSRL beamlines 7-1 and 9-1 as summarized in Table 1. Complete, high quality datasets to 1.9 Å and 2.3 Å resolution were obtained for the BAU-bound and ligand-free crystal forms, respectively. Collected data was processed and reduced by the HKL2000 package with Denzo and Scalepack . The higher resolution crystal is of the orthogonal space group P212121 with low mosaicity. The other crystal form belongs to the face-centered cubic space group F4132. Molecular replacement phasing of the data obtained on hUPP1 with BAU was successful using Molrep  with dimeric homology models of hUPP1, based on the BAU-bound E. coli UPP structure (PDB ID: 1U1C) , modified by Swiss-Model . Solution phases were sufficient to resolve density for the unmodelled BAU ligand and other unmodelled residues. The initial model was rebuilt after phases were obtained using ARP/wARP . Rounds of model building and refinement were performed using Coot  and Refmac . Due to a lack of electron-density, the first 15 residues of hUPP1 and the N-terminal cloning artifact residues 'MRGSHHHHHHGSPGLQEF' were not built. Additionally, for the same reason the final two C-terminal residues could not be modelled in the BAU-bound structure. Medium non-crystallographic symmetry restraints (between 4 chains) were retained for the loop residues 79–84 in the BAU-bound structure due to the low quality of the electron-density map in this region of the protein. The BAU-bound model includes both a BAU molecule and a phosphate ion per protein chain as ligands that could be clearly built into the electron density. The native hUPP1 structure was completed with a sulfate ion (coordinated by Arg64) and a cation (modelled as magnesium based on interatomic distances) positioned at a crystal contact point between the side chain oxygen atoms of Asp212 and Ser116 of a symmetry-related chain. The final structures were refined with Refmac to an Rfactor/Rfree of 20.5%/25.1% respectively for the BAU-bound structure, and 20.4%/22.1% for the ligand-free structure of the enzyme, with approximately 92% of residues in most favorable regions of the Ramachandran plot as analyzed by Procheck . The models were further validated using Molprobity , scoring in the 91st and 97th percentile, respectively. Figures were rendered using ICM Browser-Pro (Molsoft). The atomic coordinates and structure factors have been deposited in the Protein Data Bank (3EUF and 3EUE).
Multi-angle light scattering analysis
Recombinant hUPP1 was analyzed using size exclusion chromatography over a calibrated Superdex 200 column on an Äcta Basic FPLC (GE) with an in-line MiniDAWN TREOS light scattering detector (Wyatt Technology) for in solution characterization of absolute molecular weight, size, and quaternary assembly, in combination with an Optilab rEX refractive index detector, in accordance with the Wyatt manual. The running buffer was comprised of 300 mM KCl, 50 mM Tris buffer pH 8.0, and 1 mM TCEP.
This work was conducted in part at the Stanford Synchrotron Radiation Laboratory (SSRL) which is funded by the Department of Energy, Office of Biological and Environmental Research. We thank P. Dunten, I. Mathews, and other members of the staff of SSRL for assistance in crystallographic data collection. This work was supported by funds to TPR from the Nevada INBRE Program of the NCRR (P20 RR-016464) and a grant from the NIH to GP (R01 CA-102121).
- Cao D, Pizzorno G: Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 2004, 40: 431–443.View ArticleGoogle Scholar
- Cappiello M, Mascia L, Scolozzi C, Giorgelli F, Ipata PL: In vitro assessment of salvage pathways for pyrimidine bases in rat liver and brain. Biochim Biophys acta 1998, 1425: 273–281.View ArticlePubMedGoogle Scholar
- Tozzi MG, Camici M, Mascia L, Sgarrella F, Ipata PL: Pentose phosphates in nucleoside interconversion and catabolism. FEBS J 2006, 273: 1089–1101.View ArticlePubMedGoogle Scholar
- Morgunova EYu, Mikhailov AM, Popov AN, Blagova EV, Smirnova EA, Vainshtein BK, Mao C, Armstrong ShR, Ealick SE, Komissarov AA: Atomic structure at 2.5 Å resolution of uridine phosphorylase from E. coli as refined in the monoclinic crystal lattice. FEBS Lett 1995, 367: 183–187.View ArticlePubMedGoogle Scholar
- Burling FT, Kniewel R, Buglino JA, Chadha T, Beckwith A, Lima CD: Structure of Escherichia coli uridine phosphorylase at 2.0 Å. Acta Crystallogr D Biol Crystallogr 2003, 59: 73–76.View ArticlePubMedGoogle Scholar
- Caradoc-Davies TT, Cutfield SM, Lamont IL, Cutfield JF: Crystal structures of Escherichia coli uridine phosphorylase in two native and three complexed forms reveal basis of substrate specificity, induced conformational changes and influence of potassium. J Mol Biol 2004, 337: 337–354.View ArticlePubMedGoogle Scholar
- Bu W, Settembre EC, el Kouni MH, Ealick SE: Structural basis for inhibition of Escherichia coli uridine phosphorylase by 5-substituted acyclouridines. Acta Crystallogr D Biol Crystallogr 2005, 61: 863–872.View ArticlePubMedGoogle Scholar
- Dontsova MV, Gabdoulkhakov AG, Molchan OK, Lashkov AA, Garber MB, Mironov AS, Zhukhlistova NE, Morgunova EY, Voelter W, Betzel C, Zhang Y, Ealick SE, Mikhailov AM: Preliminary investigation of the three-dimensional structure of Salmonella typhimurium uridine phosphorylase in the crystalline state. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005, 61: 337–340.PubMed CentralView ArticlePubMedGoogle Scholar
- Pugmire MJ, Ealick SE: Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 2002, 361: 1–25.PubMed CentralView ArticlePubMedGoogle Scholar
- Watanabe S, Uchida T: Cloning and expression of human uridine phosphorylase. Biochem Biophys Res Commun 1995, 216: 265–272.View ArticlePubMedGoogle Scholar
- Johansson M: Identification of a novel human uridine phosphorylase. Biochem Biophys Res Commun 2003, 307: 41–46.View ArticlePubMedGoogle Scholar
- Cao D, Russell RL, Zhang D, Leffert JJ, Pizzorno G: Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002, 62: 2313–2317.PubMedGoogle Scholar
- Liu M, Cao D, Russell R, Handschumacher RE, Pizzorno G: Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 1998, 58: 5418–5424.PubMedGoogle Scholar
- Chu MY, Naguib FN, Iltzsch MH, el Kouni MH, Chu SH, Cha S, Calabresi P: Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine. Cancer Res 1984, 44: 1852–1856.PubMedGoogle Scholar
- Al Safarjalani ON, Rais R, Shi J, Schinazi RF, Naguib FN, el Kouni MH: Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor. Cancer Chemother Pharmacol 2006, 58: 692–698.View ArticlePubMedGoogle Scholar
- Niedzwicki JG, Chu SH, el Kouni MH, Rowe EC, Cha S: 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem Pharmacol 1982, 31: 1857–1861.View ArticlePubMedGoogle Scholar
- Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P: Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 1998, 4: 1165–1175.PubMedGoogle Scholar
- Klecker RW, Cysyk RL, Collins JM: Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Bioorg Med Chem 2006, 14: 62–66.View ArticlePubMedGoogle Scholar
- Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, Tyler PC: Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem 2003, 46: 5271–5276.View ArticlePubMedGoogle Scholar
- Russell RL, Cao D, Zhang D, Handschumacher RE, Pizzorno G: Uridine phosphorylase association with vimentin. Intracellular distribution and localization. J Biol Chem 2001, 276: 13302–13307.View ArticlePubMedGoogle Scholar
- Otwinowski Z, Minor W: Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997, 276: 307–326.View ArticleGoogle Scholar
- Collaborative Computational Project Number 4: The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994, 50: 760–763.View ArticleGoogle Scholar
- Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31: 3381–3385.PubMed CentralView ArticlePubMedGoogle Scholar
- Cohen SX, Morris RJ, Fernandez FJ, Ben Jelloul M, Kakaris M, Parthasarathy V, Lamzin VS, Kleywegt GJ, Perrakis A: Towards complete validated models in the next generation of ARP/wARP. Acta Crystallogr D Biol Crystallogr 2004, 60: 2222–2229.View ArticlePubMedGoogle Scholar
- Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60: 2126–2132.View ArticlePubMedGoogle Scholar
- Laskowski RA, Moss DS, Thornton JM: Main-chain bond lengths and bond angles in protein structures. J Mol Biol 1993, 231: 1049–1067.View ArticlePubMedGoogle Scholar
- Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, et al.: MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, 35: W375–383.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.